利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.021 秒)

    Imidazole derivatives
    2.
    发明授权
    Imidazole derivatives 失效
    咪唑衍生物

    公开(公告)号：US07078529B2

    公开(公告)日：2006-07-18

    申请号：US10818855

    申请日：2004-04-05

    申请人： Mark A. Sanner ,  Chris J. Helal ,  Christoper B. Cooper ,  Frank S. Menniti ,  Patricia A. Seymour ,  Michael K. Ahlijanian ,  Anabella Villalobos ,  Lit-Fui Lau

    发明人： Mark A. Sanner ,  Chris J. Helal ,  Christoper B. Cooper ,  Frank S. Menniti ,  Patricia A. Seymour ,  Michael K. Ahlijanian ,  Anabella Villalobos ,  Lit-Fui Lau

    IPC分类号： C07D233/88

    CPC分类号： C07D401/12 ,  C07D233/88 ,  C07D233/90 ,  C07D401/14 ,  C07D403/12 ,  C07D417/14

    摘要： The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

    摘要翻译： 本发明提供式1化合物，其中R 1，R 2，R 3，R 4和R 4均为 并且其药学上可接受的盐。 式1的化合物表示具有抑制cdk5，cdk2和GSK-3的活性。 包含式1化合物的药物组合物和方法，用于治疗和预防包括异常细胞生长（例如癌症）和神经变性疾病和病症以及受多巴胺神经传递影响的疾病和病症。 还描述了包含用于治疗雄性生育力和精子活力的式1化合物的药物组合物和方法; 糖尿病 葡萄糖耐量降低; 代谢综合征或综合征X; 多囊卵巢综合征; 脂肪生成和肥胖; 造血和虚弱，例如年龄相关的身体表现下降; 急性肌肉减少症，例如与烧伤，卧床休息，肢体固定或主要胸部，腹部和/或整形外科手术相关的肌肉萎缩和/或恶病质; 败血症 脱发，脱发，秃头; 和免疫缺陷。

    Imidazole derivatives
    3.
    发明授权
    Imidazole derivatives 失效
    咪唑衍生物

    公开(公告)号：US06756385B2

    公开(公告)日：2004-06-29

    申请号：US09919630

    申请日：2001-07-31

    申请人： Mark A. Sanner ,  Chris J. Helal ,  Christoper B. Cooper ,  Frank S. Menniti ,  Michael K. Ahlijanian ,  Annabella Villalobos ,  Lit-Fui Lau ,  Patricia A. Seymour

    发明人： Mark A. Sanner ,  Chris J. Helal ,  Christoper B. Cooper ,  Frank S. Menniti ,  Michael K. Ahlijanian ,  Annabella Villalobos ,  Lit-Fui Lau ,  Patricia A. Seymour

    IPC分类号： A61K314709

    CPC分类号： C07D401/12 ,  C07D233/88 ,  C07D233/90 ,  C07D401/14 ,  C07D403/12 ,  C07D417/14

    摘要： The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

    摘要翻译： 本发明提供了式1化合物，其中R 1，R 2，R 3和R 4如上定义，及其药学上可接受的盐。 式1的化合物表示具有抑制cdk5，cdk2和GSK-3的活性。 包含式1化合物的药物组合物和方法，用于治疗和预防包括异常细胞生长（例如癌症）和神经变性疾病和病症以及受多巴胺神经传递影响的疾病和病症。 还描述了包含用于治疗雄性生育力和精子活力的式1化合物的药物组合物和方法; 糖尿病 葡萄糖耐量降低; 代谢综合征或综合征X; 多囊卵巢综合征; 脂肪生成和肥胖; 造血和虚弱，例如年龄相关的身体表现下降; 急性肌肉减少症，例如与烧伤，卧床休息，肢体固定或主要胸部，腹部和/或整形外科手术相关的肌肉萎缩和/或恶病质; 败血症 脱发，脱发，秃头; 和免疫缺陷。

    Synergistic combinations in the treatment of anxiety
    4.
    发明授权
    Synergistic combinations in the treatment of anxiety 失效
    协调治疗放疗中的协同作用

    公开(公告)号：US5189037A

    公开(公告)日：1993-02-23

    申请号：US862392

    申请日：1992-04-02

    申请人： Patricia A. Seymour

    发明人： Patricia A. Seymour

    IPC分类号： A61K31/415 ,  A61K31/505 ,  A61K31/55

    CPC分类号： A61K31/415 ,  A61K31/505 ,  A61K31/55

    摘要： Combinations having synergistic anxiolytic activity which comprise a first component selected from the group consisting of 8-hydroxy-2-(dipropylamino)-1,2,3,4-tetrahydronaphthalene, gepirone, ipsapirone, tandospirone, (7S,9S)-2-(2-pyrimidyl)-7-(succinimidomethyl)-perhydro-1H-pyrido[1,2-a]pyrazine, or chlordiazepoxide; and a second component selected from the group consisting of 1-(2-pyrimidyl)pyrazine and idazoxan.

    摘要翻译： 具有协同抗焦虑活性的组合，其包含选自8-羟基-2-（二丙基氨基）-1,2,3,4-四氢化萘，吉哌隆，ipsapirone，坦度螺酮，（7S，9S）-2- （2-嘧啶基）-7-（琥珀酰亚氨基甲基） - 脱氢-1H-吡啶并[1,2-a]吡嗪或氯代噻吩; 和选自1-（2-嘧啶基）吡嗪和idazoxan的第二组分。